Efficacy and Durability of Immune Response after Receipt of HPV Vaccines in People Living with HIV.

ABSTRACT: People living with HIV (PLH) experience higher rates of HPV infection as well as an increased risk of HPV-related disease, including malignancies. Although they are considered a high-priority group for HPV vaccination, there are limited data regarding the long-term immunogenicity and efficacy of HPV vaccines in this population. Seroconversion rates and geometric mean titers elicited by vaccination are lower in PLH compared to immunocompetent participants, especially in individuals with CD4 counts below 200 cells/mm³ and a detectable viral load. The significance of these differences is still unclear, as a correlate of protection has not been identified. Few studies have focused on demonstrating vaccine efficacy in PLH, with variable results depending on the age at vaccination and

SUBMITTER: Losada C 

PROVIDER: S-EPMC10301114 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature